Enliven Therapeutics, Inc.(ELVN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ELVN Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Enliven Therapeutics, Inc. (ELVN), a Healthcare sector company. ELVN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Enliven Therapeutics, Inc. reports net income of $-32.5M, free cash flow of $-18.6M. Top institutional holders of ELVN by reported 13-F value include FMR, ORBIMED ADVISORS, Polar Capital Plc, based on the most recent SEC filings. ELVN trades on the Nasdaq exchange and files with the SEC under CIK 1672619. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enliven Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-32.5M
Free Cash Flow
Q2 2026
$-18.6M
ROIC
Q2 2026
-16.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-16.5% YoYOperating Income
-14.4% YoYEPS (Diluted)
+3.2% YoYTotal Assets
+46.2% YoYOp. Cash Flow
+3.9% YoYFree Cash Flow
+3.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-103.7M -16.5% | $-89.0M -24.4% | $-71.6M -90.1% | $-37.7M +26.7% | $-51.4M -24.2% | $-41.4M |
| Operating Income | $-119.7M -14.4% | $-104.6M -25.2% | $-83.5M -115.3% | $-38.8M +24.6% | $-51.4M -23.4% | $-41.7M |
| EPS (Diluted) | $-1.83 +3.2% | $-1.89 +6.0% | $-2.01 +83.3% | $-12.05 -408.4% | $-2.37 | — |
| Total Assets | $476.2M +46.2% | $325.8M +19.8% | $271.9M +226.4% | $83.3M -11.1% | $93.6M +3.1% | $90.8M |
| Operating Cash Flow | $-70.3M +3.9% | $-73.2M -19.5% | $-61.3M -91.0% | $-32.1M +31.4% | $-46.8M -25.1% | $-37.4M |
| Free Cash Flow | $-70.5M +3.8% | $-73.2M -19.2% | $-61.4M -87.9% | $-32.7M +30.1% | $-46.8M -25.0% | $-37.4M |
Get alerted when ELVN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Enliven Therapeutics, Inc. including:
Top Institutional Holders of ELVN
FMR LLC
$508.8M10,025,017 shORBIMED ADVISORS LLC
$343.9M6,776,632 shPolar Capital Holdings Plc
$326.4M6,430,636 shBlackRock, Inc.
$221.3M4,359,704 shVestal Point Capital, LP
$203.0M4,000,000 shCommodore Capital LP
$166.2M3,275,000 shPRICE T ROWE ASSOCIATES INC /MD/
$147.4M2,903,907 shVANGUARD CAPITAL MANAGEMENT LLC
$130.4M2,569,002 shCITADEL ADVISORS LLC
$105.0M2,068,992 shFairmount Funds Management LLC
$94.2M1,855,644 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $508.8M | 10,025,017 |
| ORBIMED ADVISORS LLC | $343.9M | 6,776,632 |
| Polar Capital Holdings Plc | $326.4M | 6,430,636 |
| BlackRock, Inc. | $221.3M | 4,359,704 |
| Vestal Point Capital, LP | $203.0M | 4,000,000 |
| Commodore Capital LP | $166.2M | 3,275,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $147.4M | 2,903,907 |
| VANGUARD CAPITAL MANAGEMENT LLC | $130.4M | 2,569,002 |
| CITADEL ADVISORS LLC | $105.0M | 2,068,992 |
| Fairmount Funds Management LLC | $94.2M | 1,855,644 |
More Healthcare Companies
View all Healthcare →Put ELVN on your watchlist
Track score changes the day Enliven Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ELVN a good stock to buy?
13F Pro's AI-powered analysis of Enliven Therapeutics, Inc. (ELVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELVN are available on the ELVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ELVN is classified as a mid company.
Which hedge funds own ELVN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Enliven Therapeutics, Inc.'s investment landscape.